&lt;p&gt;Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes&lt;/p&gt;

Takahara, Mitsuyoshi; Shiraiwa, Toshihiko; Matsuoka, Taka‐aki; Yamamoto, Kaoru; Maeno, Yoshifumi; Shiraiwa, Y; Yoshida, Yoko; Katakami, Naoto; Iijima, Hiroaki; Katsumata, Hideyuki; Akita, Keiichi; Hashimoto, Takeji; Shimomura, Iichiro

doi:10.2147/dmso.s273396

Cited by 1 publication

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…139,140,145,146 Long-term use of SGLT2i(s) showed improved sensitivity of beta-cells to glucose while on treatment. 147,148 Takahara et al reported two separate studies showing improvements in glucose levels, insulin secretion and DI with 4 weeks of treatment with ipragliflozin and 24 weeks of treatment with canagliflozin; benefits were sustained after a 1-week "washout" period 149,150 It may be worth noting that the average duration of diabetes in the latter study was more than 10 years. 150 At present, it is difficult to definitively conclude that there is a positive effect of SGLT2i(s) on beta-cell function.…”

Section: Sodium-glucose Cotransporter-2 Inhibitorsmentioning

confidence: 99%

Beta‐cell function in type 2 diabetes (T2DM): Can it be preserved or enhanced?

Kassem

Rajpal

Barreiro

et al. 2023

Journal of Diabetes

View full text Add to dashboard Cite

Type 2 diabetes (T2DM) is a complex metabolic disorder manifested by hyperglycemia, insulin resistance, and deteriorating beta‐cell function. A way to prevent progression of the disease might be to enhance beta‐cell function and insulin secretion. However, most previous studies examined beta‐cell function while patients were using glycemia‐lowering agents without an adequate period off medications (washout). In the present review we focus on studies with a washout period. We performed a literature search (2010 to June 2021) using beta‐cell function and enhancement. The evidence shows that beta‐cell function can be enhanced. Bariatric surgery and very low calorie diets show improvement in beta‐cell function in many individuals. In addition, use of glucagon‐like peptide‐1 receptor agonists for prolonged periods (3 years or more) can also lead to improvement of beta‐cell function. Further research is needed to understand the mechanisms leading to improved beta‐cell function and identify agents that could enhance beta‐cell function in patients with T2DM.

show abstract